News coverage about Anika Therapeutics (NASDAQ:ANIK) has trended somewhat positive on Saturday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anika Therapeutics earned a news impact score of 0.20 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.1193795497894 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- North America and Europe Dermal Filler Market Value to Reach US$ 2,800.4 Mn by 2026 End (reports.pr-inside.com)
- Anika (ANIK) Grows in Orthopedic Medicines on Positive Data (finance.yahoo.com)
- ETFs with exposure to Anika Therapeutics, Inc. : August 15, 2017 (finance.yahoo.com)
- Facial Injectables Market Is Expected To Grow At A CAGR Of 11.5% From 2014 To 2025: Grand View Research, Inc. (medgadget.com)
A number of analysts have recently weighed in on the stock. BidaskClub raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 8th. Zacks Investment Research raised shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd.
Shares of Anika Therapeutics (NASDAQ:ANIK) opened at 52.82 on Friday. Anika Therapeutics has a one year low of $41.38 and a one year high of $53.99. The company has a market cap of $774.24 million, a P/E ratio of 23.47 and a beta of 1.69. The stock’s 50 day moving average is $49.79 and its 200-day moving average is $47.14.
Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.32. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The company had revenue of $33.50 million during the quarter, compared to analyst estimates of $27.20 million. During the same period last year, the business earned $0.57 earnings per share. Anika Therapeutics’s revenue was up 25.9% compared to the same quarter last year. Equities research analysts forecast that Anika Therapeutics will post $2.20 earnings per share for the current year.
In other Anika Therapeutics news, Director Jeffery S. Thompson sold 10,725 shares of Anika Therapeutics stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $47.39, for a total transaction of $508,257.75. Following the completion of the sale, the director now directly owns 15,845 shares in the company, valued at $750,894.55. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Charles H. Sherwood sold 63,799 shares of Anika Therapeutics stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the sale, the chief executive officer now owns 174,705 shares of the company’s stock, valued at $8,873,266.95. The disclosure for this sale can be found here. Insiders sold 88,725 shares of company stock valued at $4,459,085 over the last 90 days. 6.57% of the stock is owned by company insiders.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
